Clinical course of COVID-19 infection in paediatric familial Mediterranean fever patients

To evaluate the course of coronavirus-19 (COVID-19) infection in paediatric familial Mediterranean fever (FMF) patients and to investigate the risk factors for COVID-19 infection. Medical records of 100 consecutive paediatric FMF patients and their COVID-19 infection status were evaluated. Age- and...

Full description

Saved in:
Bibliographic Details
Published inModern rheumatology Vol. 32; no. 2; pp. 467 - 472
Main Authors Kaya Akca, Ummusen, Sener, Seher, Balık, Zeynep, Gurlevik, Sibel, Oygar, Pembe Derin, Atalay, Erdal, Cuceoglu, Muserref Kasap, Basaran, Ozge, Batu, Ezgi Deniz, Teksam, Ozlem, Bilginer, Yelda, Ozsurekci, Yasemin, Ozen, Seza
Format Journal Article
LanguageEnglish
Published England 28.02.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:To evaluate the course of coronavirus-19 (COVID-19) infection in paediatric familial Mediterranean fever (FMF) patients and to investigate the risk factors for COVID-19 infection. Medical records of 100 consecutive paediatric FMF patients and their COVID-19 infection status were evaluated. Age- and gender-matched control group consisted of 51 patients with positive results for severe acute respiratory syndrome coronavirus 2. Twenty-five of 100 paediatric FMF patients were detected to have COVID-19 infection. A history of contact with a COVID-19 case was present in ∼95% of patients in both the FMF and control groups with COVID-19 infection. Asymptomatic infection was detected in two patients in the paediatric FMF group (8.0%) and 17 patients in the control group (33.3%) (P = .017). Mild disease was observed in 23 paediatric FMF patients (92.0%) and 28 control patients (54.9%) (P = .001), whereas moderate disease was present in only 6 control patients (11.7%) (0 vs 11.7%, P = .074). Severe or critical disease was not observed in any patients. Paediatric FMF patients receiving colchicine had no moderate COVID-19 disease compared to the control group. We suggest that colchicine use may tune down the severity of the disease even if it does not prevent COVID-19 infection.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1439-7595
1439-7609
DOI:10.1093/mr/roab056